
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. is positioned positively due to the encouraging biomarker and safety data for its lead candidate PMN310, suggesting a mechanistic advantage that could enhance investor confidence ahead of forthcoming clinical data. The dual selectivity profile of PMN267 reveals its potential for broad application in TDP-43-driven neurodegenerative diseases, indicating significant development opportunities that could lead to substantial market demand. Furthermore, the absence of adverse effects typically associated with other marketed anti-amyloid treatments enhances PMN310's prospects, underscoring the company's strong developmental framework and its potential for sustained financial growth.
Bears say
ProMIS Neurosciences has reported a significant net loss of $11.6 million for the third quarter of 2025, translating to a loss of $0.24 per share, which underscores ongoing financial challenges and a lack of profitability. Furthermore, the company's reliance on complex mechanisms associated with Alzheimer's disease, such as soluble Aβ oligomers, raises concerns about the efficacy of its treatments, particularly given the history of failed therapies facing similar challenges. Additionally, the presence of potential partnership risks, competition impacting market uptake, and looming dilution risk may further hinder ProMIS's financial stability and stock performance.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares